|Bid||6.14 x 1400|
|Ask||6.25 x 800|
|Day's range||6.10 - 6.75|
|52-week range||2.23 - 24.90|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||13.33|
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. On Feb. 3, Vaxart announced that its oral coronavirus-vaccine candidate, VXA-CoV2-1, did not induce neutralizing antibodies after a one-dose regimen. The discrepancy here puzzled many investors since the two should be in tandem with one another, as with of the coronavirus vaccines currently on the market.
As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.